KU-32 | CAS# 956498-70-7 | Hsp90 Inhibitor

MedKoo Cat#: 565021 | Name: KU-32

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KU-32 is a C-terminal inhibitor of Hsp90 which increases Hsp70 expression, and protects against neuronal glucotoxicity and reverses multiple clinical indices of diabetic peripheral neuropathy.

Chemical Structure

KU-32

CAS#956498-70-7

Theoretical Analysis

MedKoo Cat#: 565021

Name: KU-32

CAS#: 956498-70-7

Chemical Formula: C20H25NO8

Exact Mass: 407.1580

Molecular Weight: 407.42

Elemental Analysis: C, 58.96; H, 6.19; N, 3.44; O, 31.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

KU32; KU 32; KU-32

IUPAC/Chemical Name

N-(7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-8-methyl-2-oxo-2H-chromen-3-yl)acetamide

InChi Key

KJAWXHNSLFJNTM-BUIAKZPTSA-N

InChi Code

InChI=1S/C20H25NO8/c1-9-13(27-19-15(24)14(23)17(26-5)20(3,4)29-19)7-6-11-8-12(21-10(2)22)18(25)28-16(9)11/h6-8,14-15,17,19,23-24H,1-5H3,(H,21,22)/t14-,15+,17+,19+/m0/s1

SMILES Code

CC(NC(C1=O)=CC2=C(O1)C(C)=C(O[C@H]3[C@H](O)[C@H](O)[C@@H](OC)C(C)(C)O3)C=C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 407.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chatterjee BK, Jayaraj A, Kumar V, Blagg B, Davis RE, Jayaram B, Deep S, Chaudhuri TK. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32. J Biol Chem. 2019 Feb 21. pii: jbc.RA118.002502. doi: 10.1074/jbc.RA118.002502. [Epub ahead of print] PubMed PMID: 30792306. 2: Farmer K, Williams SJ, Novikova L, Ramachandran K, Rawal S, Blagg BS, Dobrowsky R, Stehno-Bittel L. KU-32, a novel drug for diabetic neuropathy, is safe for human islets and improves in vitro insulin secretion and viability. Exp Diabetes Res. 2012;2012:671673. doi: 10.1155/2012/671673. Epub 2012 Nov 1. PubMed PMID: 23197975; PubMed Central PMCID: PMC3503326. 3: Sofis MJ, Jarmolowicz DP, Kaplan SV, Gehringer RC, Lemley SM, Garg G, Blagg BS, Johnson MA. KU32 prevents 5-fluorouracil induced cognitive impairment. Behav Brain Res. 2017 Jun 30;329:186-190. doi: 10.1016/j.bbr.2017.03.042. Epub 2017 Mar 27. PubMed PMID: 28359881; PubMed Central PMCID: PMC5846472. 4: Kumar Mv V, Ebna Noor R, Davis RE, Zhang Z, Sipavicius E, Keramisanou D, Blagg BSJ, Gelis I. Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain. Medchemcomm. 2018 Jul 2;9(8):1323-1331. doi: 10.1039/c8md00151k. eCollection 2018 Aug 1. PubMed PMID: 30151087; PubMed Central PMCID: PMC6097425. 5: Forsberg LK, Anyika M, You Z, Emery S, McMullen M, Dobrowsky RT, Blagg BSJ. Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects. Eur J Med Chem. 2018 Jan 1;143:1428-1435. doi: 10.1016/j.ejmech.2017.10.038. Epub 2017 Oct 18. PubMed PMID: 29137866; PubMed Central PMCID: PMC5736410. 6: Zhang X, Li C, Fowler SC, Zhang Z, Blagg BSJ, Dobrowsky RT. Targeting Heat Shock Protein 70 to Ameliorate c-Jun Expression and Improve Demyelinating Neuropathy. ACS Chem Neurosci. 2018 Feb 21;9(2):381-390. doi: 10.1021/acschemneuro.7b00377. Epub 2017 Nov 9. PubMed PMID: 29120605; PubMed Central PMCID: PMC5821551. 7: Anyika M, McMullen M, Forsberg LK, Dobrowsky RT, Blagg BS. Development of Noviomimetics as C-Terminal Hsp90 Inhibitors. ACS Med Chem Lett. 2015 Dec 9;7(1):67-71. doi: 10.1021/acsmedchemlett.5b00331. eCollection 2016 Jan 14. PubMed PMID: 26819668; PubMed Central PMCID: PMC4716602. 8: Ma J, Pan P, Anyika M, Blagg BS, Dobrowsky RT. Modulating Molecular Chaperones Improves Mitochondrial Bioenergetics and Decreases the Inflammatory Transcriptome in Diabetic Sensory Neurons. ACS Chem Neurosci. 2015 Sep 16;6(9):1637-48. doi: 10.1021/acschemneuro.5b00165. Epub 2015 Jul 22. PubMed PMID: 26161583; PubMed Central PMCID: PMC4573952. 9: Zhao H, Anyika M, Girgis A, Blagg BS. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines. Bioorg Med Chem Lett. 2014 Aug 1;24(15):3633-7. doi: 10.1016/j.bmcl.2014.05.020. Epub 2014 May 16. PubMed PMID: 24953820; PubMed Central PMCID: PMC4096108. 10: Ma J, Farmer KL, Pan P, Urban MJ, Zhao H, Blagg BS, Dobrowsky RT. Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J Pharmacol Exp Ther. 2014 Feb;348(2):281-92. doi: 10.1124/jpet.113.210435. Epub 2013 Nov 21. PubMed PMID: 24263156; PubMed Central PMCID: PMC3912549. 11: Li C, Ma J, Zhao H, Blagg BS, Dobrowsky RT. Induction of heat shock protein 70 (Hsp70) prevents neuregulin-induced demyelination by enhancing the proteasomal clearance of c-Jun. ASN Neuro. 2012 Dec 6;4(7):e00102. doi: 10.1042/20120047. PubMed PMID: 23240583; PubMed Central PMCID: PMC3517131. 12: Kusuma BR, Zhang L, Sundstrom T, Peterson LB, Dobrowsky RT, Blagg BS. Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. J Med Chem. 2012 Jun 28;55(12):5797-812. doi: 10.1021/jm300544c. Epub 2012 Jun 15. PubMed PMID: 22702513; PubMed Central PMCID: PMC3390240. 13: Urban MJ, Pan P, Farmer KL, Zhao H, Blagg BS, Dobrowsky RT. Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol. 2012 May;235(1):388-96. doi: 10.1016/j.expneurol.2012.03.005. Epub 2012 Mar 20. PubMed PMID: 22465570; PubMed Central PMCID: PMC3336191. 14: Zhang L, Zhao H, Blagg BS, Dobrowsky RT. C-terminal heat shock protein 90 inhibitor decreases hyperglycemia-induced oxidative stress and improves mitochondrial bioenergetics in sensory neurons. J Proteome Res. 2012 Apr 6;11(4):2581-93. doi: 10.1021/pr300056m. Epub 2012 Mar 28. PubMed PMID: 22413817; PubMed Central PMCID: PMC3329766. 15: Urban MJ, Li C, Yu C, Lu Y, Krise JM, McIntosh MP, Rajewski RA, Blagg BS, Dobrowsky RT. Inhibiting heat-shock protein 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro. 2010 Aug 11;2(4):e00040. doi: 10.1042/AN20100015. PubMed PMID: 20711301; PubMed Central PMCID: PMC2919983.